Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BHVN
BHVN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BHVN News
Biohaven Completes Enrollment in RISE3 Study for Opakalim
Jun 30 2026
PRnewswire
Biohaven Completes Enrollment in RISE3 Study for Opakalim
Jun 30 2026
Newsfilter
BofA Downgrades Biohaven Rating and Price Target
Jun 30 2026
stocktwits
U.S. Stocks Close Higher, Led by Technology Gains
Jun 29 2026
NASDAQ.COM
US Stocks Rise, Led by Technology Sector Gains
Jun 29 2026
NASDAQ.COM
US Stocks Rise, Led by Technology Sector Gains
Jun 29 2026
NASDAQ.COM
Biohaven Initiates Pivotal Phase 3 Trial for Graves' Disease
Jun 29 2026
PRnewswire
Biohaven Launches Pivotal Trial for BHV-1300 in Graves' Disease
Jun 29 2026
Newsfilter
Biohaven and Hubbell Options Trading Active
Jun 17 2026
NASDAQ.COM
Valuation Analysis of U.S. Small-Cap Healthcare Stocks
Jun 02 2026
seekingalpha
Biohaven Initiates First-in-Human Dosing for BHV-8100, a Novel PKM2 Modulator
Jun 01 2026
PRnewswire
Biohaven Initiates First-in-Human Study for BHV-8100, a Novel PKM2 Modulator
Jun 01 2026
Newsfilter
Biohaven Reports New Clinical Data on Innovative Therapies
May 27 2026
PRnewswire
Biohaven's New Therapies Show Significant Antibody Reduction
May 27 2026
Newsfilter
Biohaven Reports New Data on Opakalim for Epilepsy Treatment
May 26 2026
PRnewswire
Biohaven Reports New Clinical Data on Opakalim for Epilepsy Treatment
May 26 2026
Newsfilter
Show More News
